Lupin Ltd — Board/Management Information 2024

Apr 3, 2024

==> picture [79 x 93] intentionally omitted <==

April 3, 2024

 BSE Limited

Department of Corporate Services, P. J. Towers, Dalai Street, MUMBAI - 400 001.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’).

We are pleased to enclose a Press Release regarding the appointment of Dr. Ranjana Pathak as Chief Quality Officer of the Company succeeding Mr. Johnny Mikell who will be retiring from the services of the Company. With over three decades of industry experience, Dr. Pathak brings a wealth of expertise and leadership and will oversee all aspects of quality and regulatory compliance for the Company’s global operations.

The above may kindly be considered as disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e 2abcf74700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726 cdb67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2024.04.03 14:59:21 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl: a/a

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer

Mumbai, April 3, 2024 : Global pharma major Lupin Limited (Lupin) today announced the appointment of Dr. Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring from the services of the company. With over three decades of industry experience, Dr. Pathak brings a wealth of expertise and leadership and will oversee all aspects of quality and regulatory compliance for Lupin’s global operations.

Dr. Pathak’s career includes serving as the Global Head for Quality and Pharmacovigilance at Dr. Reddy’s. Prior to this, Dr. Pathak served as the President & Global Head of Quality, Medical Affairs and Pharmacovigilance at Cipla and has also held Global Quality and Compliance leadership positions at Watson/Actavis and Endo Pharmaceuticals in the U.S. Dr. Pathak has strong experience across generic and brand medicines across dosage platforms including injectables, inhalation products and biologics.

“We extend our gratitude to Johnny for his valuable contribution to Lupin over the past five years,” said Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin . “We are delighted to welcome Ranjana to our executive leadership team. Her extensive global experience and proven track record in building and sustaining a strong culture of quality and compliance align with Lupin’s commitment to be best-in-class in delivering quality products to the communities we serve.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector. Please visit www.lupin.com for more information.

Follow us on:

Twitter: https://twitter.com/LupinGlobal LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Page 1 of 2

Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO

==> picture [68 x 70] intentionally omitted <==

BLOOMBERG: LPCIN

Heena Dhedhi

Deputy General Manager - Corporate Communications Email: heenadhedhi@lupin.com

Page 2 of 2